Cancer biomarker

From WikiMD's WELLNESSPEDIA

Cancer biomarkers are substances or processes that are indicative of the presence of cancer in the body. A biomarker may be a molecule secreted by a tumor or a specific response of the body to the presence of cancer. Genetic, epigenetic, proteomic, glycomic, and imaging biomarkers can be used for cancer diagnosis, prognosis, and epidemiology. Ideally, such biomarkers can be assayed in non-invasively collected biofluids like blood or serum.

Types of Cancer Biomarkers[edit]

Cancer biomarkers can be classified into several types based on their application and the nature of the biomarkers. These include:

  • Diagnostic biomarkers: Help in identifying the presence of cancer.
  • Prognostic biomarkers: Provide information about the patient's overall outcome, regardless of therapy.
  • Predictive biomarkers: Predict the response of a cancer to a particular treatment.
  • Pharmacodynamic biomarkers: Indicate whether a drug is effective in the target area of the body.
  • Early detection biomarkers: Used to detect cancer at an early stage, potentially before symptoms appear.

Examples of Cancer Biomarkers[edit]

Some well-known examples of cancer biomarkers include:

  • Prostate-specific antigen (PSA): Used for the screening and monitoring of prostate cancer.
  • CA-125: Used for the detection and monitoring of ovarian cancer.
  • HER2/neu receptor: Overexpression is associated with certain types of breast cancer and can predict response to targeted therapy.
  • BRAF V600E: Mutation associated with various cancers, including melanoma, colorectal cancer, and others, which can influence treatment decisions.

Challenges and Future Directions[edit]

While cancer biomarkers hold great promise for the management of cancer, there are several challenges to their effective use. These include the need for validation of biomarker specificity and sensitivity, the development of cost-effective tests for widespread use, and the integration of biomarker testing into clinical practice. Future research is focused on identifying new biomarkers, improving the accuracy and reliability of existing markers, and developing personalized medicine approaches that tailor treatment to individual patients based on their biomarker profile.

See Also[edit]

Stub icon

This oncology article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Cancer_biomarker&oldid=6314855"